$3.13
2.19% yesterday
Nasdaq, Jun 27, 10:02 pm CET
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Arbutus Biopharma Corporation Stock price

$3.13
-0.32 9.28% 1M
-0.08 2.49% 6M
-0.14 4.28% YTD
+0.03 0.97% 1Y
+0.45 16.79% 3Y
+1.21 63.02% 5Y
-8.68 73.50% 10Y
-4.09 56.64% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.07 2.19%
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Key metrics

Basic
Market capitalization
$599.5m
Enterprise Value
$486.8m
Net debt
$-112.7m
Cash
$112.7m
Shares outstanding
191.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
93.67 | 93.99
EV/Sales
76.06 | 76.32
EV/FCF
negative
P/B
7.57
Financial Health
Equity Ratio
73.93%
Return on Equity
-71.81%
ROCE
-68.21%
ROIC
-
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$6.4m | $6.4m
EBITDA
$-65.2m | -
EBIT
$-66.6m
Net Income
$-76.6m | $-52.3m
Free Cash Flow
$-59.0m
Growth (TTM | estimate)
Revenue
-50.73% | 3.37%
EBITDA
17.07% | -
EBIT
16.86%
Net Income
-2.94% | 25.27%
Free Cash Flow
25.19%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,018.38% | -
EBIT
-1,039.54%
Net
-1,195.86% | -819.15%
Free Cash Flow
-921.96%
More
EPS
$-0.40
FCF per Share
$-0.31
Short interest
9.52%
Employees
44.00
Rev per Employee
$140.00k
Show more

Is Arbutus Biopharma Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Arbutus Biopharma Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Arbutus Biopharma Corporation forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Arbutus Biopharma Corporation forecast:

Buy
80%
Hold
20%

Financial data from Arbutus Biopharma Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
6.40 6.40
51% 51%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
2% 2%
354%
- Research and Development Expense 48 48
33% 33%
744%
-65 -65
17% 17%
-1,019%
- Depreciation and Amortization 1.36 1.36
5% 5%
21%
EBIT (Operating Income) EBIT -67 -67
17% 17%
-1,040%
Net Profit -77 -77
3% 3%
-1,196%

In millions USD.

Don't miss a Thing! We will send you all news about Arbutus Biopharma Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arbutus Biopharma Corporation Stock News

Neutral
GlobeNewsWire
3 days ago
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China
Neutral
GlobeNewsWire
about 2 months ago
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no  interferon
Neutral
GlobeNewsWire
about 2 months ago
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER...
More Arbutus Biopharma Corporation News

Company Profile

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Head office Canada
CEO Lindsay Androski
Employees 44
Founded 2005
Website www.arbutusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today